United Guardian Inc  (UG)
Other Ticker:  
Price: $9.4000 $0.04 0.427%
Day's High: $9.6131 Week Perf: 3.07 %
Day's Low: $ 9.27 30 Day Perf: -11.74 %
Volume (M): 5 52 Wk High: $ 26.09
Volume (M$): $ 46 52 Wk Avg: $14.28
Open: $9.27 52 Wk Low: $9.03

 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 5
 Employees 34
 Revenues (TTM) (Millions $) 13
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

United Guardian Inc

United-Guardian, Inc. is a Delaware corporation that, through its Guardian Laboratories Division ("Guardian"), manufactures and markets cosmetic ingredients, personal care products, pharmaceuticals, medical lubricants, health care products, and specialty industrial products. It also conducts research and product development, primarily related to the development of new and unique cosmetic and personal care products. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products.

United's predecessor, United International Research, Inc. ("UIR"), was founded and incorporated in New York in 1942 by Dr. Alfred R. Globus, United's Chairman and Director of Research until his death on April 9, 2009. On February 10, 1982, a merger took place between UIR and Guardian Chemical Corp. ("GCC"), an affiliate of UIR, whereby GCC was merged into UIR and the name was changed to United-Guardian, Inc., a New York corporation. On September 14, 1987, United-Guardian, Inc. (New York) was merged with and into a newly-formed Delaware corporation by the same name, United-Guardian, Inc., for the purpose of changing the domicile of the Company to Delaware.

The Company manufactures and markets cosmetic ingredients, personal and health care products, medical lubricants, pharmaceuticals, and specialty industrial products. It also conducts research and development, primarily related to the development of new and unique cosmetic and personal care products. The Company focuses on the development of products that fill unmet market needs, have unique properties, and use proprietary technology that it sometimes protects with patents. Many of the Company's products are marketed through collaborative agreements with larger companies. The personal care products manufactured by the Company, including the cosmetic ingredients, are marketed to end users through the Company's worldwide network of marketing partners and distributors, and are currently used by many of the major manufacturers of cosmetic and personal care products. The Company sells product outright to its marketing partners, Ex Works (EXW) the Company’s plant in Hauppauge, New York. Those marketing partners in turn resell those products to their customers, who are typically the manufacturers and marketers of cosmetic and personal care products, and who in turn utilize the Company’s products in their finished products. The products are not sold on a consignment basis, so unless a product is determined to be defective it is not returnable except at the discretion of the Company.

The Company operates in one business segment. The Company’s products are separated into four distinct product categories: personal care products (including cosmetic ingredients), pharmaceuticals, medical products, and industrial products. Each product category is marketed differently.

The Company’s personal care products, including cosmetic ingredients, are marketed globally by six marketing partners, of which Ashland Specialty Ingredients (“ASI”), a business segment of Ashland, Inc., is the largest. The products are sold directly to those marketing partners, which in turn resell those products to its customers for use in the manufacture or compounding of the customers’ personal care and cosmetic products. The Company’s non-pharmaceutical medical products (referred to hereinafter as “medical products”) and the specialty industrial products are sold directly by the Company to the end users or to contract manufacturers utilized by the end users. The Company’s pharmaceutical products are marketed by direct advertising, mailings, and trade exhibitions, and are sold to hospitals and pharmacies primarily through full-line drug wholesalers, which purchase the Company’s products outright for resale to their customers. The Company also sells a small quantity of pharmaceutical products directly to hospitals and pharmacies. The Company's products are sold under trademarks or trade names owned by the Company, some of which are registered with the United States Patent and Trademark Office as well as comparable regulatory agencies in some foreign countries.

   Company Address: 230 Marcus Blvd. Hauppauge 11788 NY
   Company Phone Number: 273-0900   Stock Exchange / Ticker: NASDAQ UG
   UG is expected to report next financial results on May 12, 2023.

Customers Net Income fell by UG's Customers Net Profit Margin fell to

-32.44 %

11.05 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
CE        7.2% 
DOW        5.87% 
EMN        5.98% 
FMC        3.77% 
HUN        1.67% 
IFF        9.13% 
• View Complete Report

Htg Molecular Diagnostics Inc

Deficit on Weak Sales the HTGM during the fiscal fourth quarter of 2022

For the October to December 31 2022 period company lost money of $-0.43 per share compare to $-0.69 a year ago and surged loss from $-0.41 per share from the prior reporting period.

Sales declined respectably by -15.216 % to $2.44 millions from $2.88 millions in the same reporting period a year ago and sequentially Sales surged by 95.007 % from $1.25 millions.

International Stem Cell Corporation

Healthy conduct by the company over the financial interval ending December 31 2022

ISCO reached balanced books at $0.00 per share in the financial interval ending December 31 2022, although its Sales surged by 31.85 % to $2.43 millions from the similar quarter a year prior.

In8bio Inc

Biotechnology & Pharmaceuticals company, reduction in the business behavior all over fiscal fourth quarter of 2022

The stockholders have not hoped for some changes at the revenue all over the October to December 31 2022 reporting cycle at the company. But, they pay close attention to INABs' operating loss that has been at $-7.798 millions, during the same period.

Icosavax Inc

Underlining the fiscal interval closing Dec 31 2022 ICVX Losses have swelled at $-0.44 per share, relative to the earnings of $1.76 per share a year before quarter, In the previous quarter ICVX realized $-0.55 per share.

Eledon Pharmaceuticals Inc

Business costs have been on the rise at the ELDN in the most recent fiscal period

As the October to December 31 2022 reporting season resumes, the most businesses have announced the results. In the thick of it, are several businesses in the Major Pharmaceutical Preparations sector. And today, ELDN issued operating shortfall of $-58.688 millions, for the most recent fiscal period.


United Guardian Inc's Segments
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

PNHT's Profile

Stock Price

PNHT's Financials

Business Description


Charts & Quotes

PNHT's News


PNHT's Competitors

Customers & Markets

Economic Indicators

PNHT's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071